All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 800+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Ipsen lands EC approval for Kayfanda in rare liver disease
Small molecule, cholestatic pruritus in Alagille Syndrome - Read more

Sanofi scores first-line approval for Sarclisa in multiple myeloma, directly competing with Johnson & Johnson’s Darzalex
Monoclonal antibody, multiple myeloma, cancer - Read more

UCB’s Bimzelx scores FDA approval for triad of autoimmune disorders
Monoclonal antibody, active psoriatic arthritis, non-radiographic axial spondyloarthritis, active ankylosing spondylitis - Read more

LEO Pharma’s topical Anzupgo’s EC approval for chronic hand eczema
Small molecule, chronic hand eczema - Read more

THE GOOD
Business Development

Sanofi buys exclusive rights to Ventyx Biosciences’ VTX3232 for $27M
Small molecule, Parkinson’s disease, obesity - Read more

Context Therapeutics buys global rights to bispecific antibody BA3362 from BioAlta for $11M upfront, $122.5M biobucks
Bispecific antibody, solid tumor, cancer - Read more

THE GOOD
Clinical Trials

Black Diamond Therapeutics stock pops (then returns to earth) after encouraging Ph2 initial data for BDTX-1535
Small molecule, oral cancer - Read more

Biohaven present positive pivotal data for troriluzole in spinocerebellar ataxia
Small molecule, spinocerebellar ataxia - Read more

Ideaya Biosciences posts positive interim Ph2 data for darovasertib in neoadjuvant uveal melanoma
Small molecule, melanoma, cancer - Read more

Teva Pharmaceuticals’ showcases once-monthly subcutaneous olanzapine safety data in Ph1, with primary endpoint hit for Ph3
Small molecule, schizophrenia - Read more

ORYZON Genomics touts vafidemstat Ph2b data in borderline personality disorder
Small molecule, borderline personality disorder - Read more

⬇️ The Good News (Cont’d) ⬇️

THE GOOD
Fundraises

ViceBio $100M raise for “next-generation [respiratory illness] vaccines”
Vaccine, respiratory syncytial virus, human metapneumovirus - Read more

THE GOOD
IPOs

CAMP4 Therapeutics files for $75M IPO
RNA, urea cycle disorder - Read more

THE GOOD
Mergers & Acquisitions

Telix Pharmaceuticals radios in $230M upfront + $20M biobucks to purchase RLS Radiopharmacies, vertical integration play
Radiopharma, radiopharmacy - Read more

VaLogic acquires life science facility firm Facility Logix
Life science facility building, GxP compliance platform - Read more

Longevity Biomedical acquired by SPAC FutureTech II Acquisition Corp. to go public on NASDAQ
Allogeneic tissue biomaterial, soft tissue reconstruction, medical device, stroke, retinal vein occlusion - Read more

THE GOOD
Partnerships

Nicox, Glaukos preclinical research partnership for NCX 1728, option for licensing agreement in the future
Small molecule, intraocular pressure, ophthalmic disorders - Read more

THE GOOD
Research

A potential surgery-free solution to cataracts might be found in…hibernating squirrels?
Cataracts - Read more  

THE GOOD
Strategic Plans

Rejuveron Life Sciences rebrands to Centenara Labs
Longevity medicine, corporate rebrand - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Clinical Trials

AstraZeneca, Daiichi Sankyo’s breast cancer ADC hopeful datopotamab deruxtecan stumbles in Ph3, inadequate survival benefit
Antibody-drug conjugate, breast cancer - Read more

THE BAD
Politics & Policy

Eli Lilly, Amgen in the hot seat as Sen. Cassidy (R-LA) wants answer for their 340B contract pharmacy restrictions
340B drug pricing, contract pharmacy - Read more

THE UGLY
Lawsuits

Johnson & Johnson raises talc settlement offer to $8B as “Texas two-step” legal strategy continues
Talc, ovarian cancer - Read more

THE UGLY
Public Health

CDC acknowledges that a second healthcare worker had bird flu respiratory symptoms but was never tested
H5N1 bird flu, infectious disease - Read more [Paywall]

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.